- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00944684
High Dose Ribavirin in the Treatment of Chronic Hepatitis C
Prospective, Open-label, Randomised Controlled Trial on Efficacy and Tolerability of PegIFN-alpha 2a + Serum Level-adapted RBV vs. PegIFN-alpha 2a + Weight-based RBV in Treatment-naive Patients With Chronic Hepatitis C Genotype 1
Treatment of patients with chronic hepatitis C infected with genotype 1 hepatitis C virus (HCV) consists of combined peginterferon/ribavirin for 48 weeks. Approximately 50% of patients experience sustained virological response which equals cure. All other patients either do not respond or experience recurrence of HCV virus and chronic hepatitis. Important predictors of successful treatment are sustained dosing of both peginterferon and ribavirin. With regard to the latter, clinical evidence indicates that higher ribavirin doses may in fact even improve treatment outcome. However, high ribavirin doses cause hemolytic anemia which require dose reductions. Recent clinical experience show that erythropoetic growth factors, including erythropoetin, can counteract hemolytic anemia caused by antiviral treatment in chronic hepatitis C patients. Therefore, the current trial aims to test whether higher ribavirin doses adapted to a target plasma concentrations instead of a weight-based dosing result in better healing rates, and whether ribavirin-associated hemolytic anemia can be compensated by concommitant erythropoetin treatment.
Using a randomized, controlled, open-label design, the investigators hypothesize that patients with high ribavirin doses adapted to plasma levels experience better viral clearance than patients treated with standard weight-based ribavirin doses. In addition, the investigators hypothesize that erythropoetin treatment will counteract hemolytic anemia induced by ribavirin thereby allowing maintenance of target plasma concentrations without ribavirin dose reductions.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Background
Prevalence and incidence of chronic hepatitis C (CHC) are rising worldwide. Complications include chronic liver failure and hepatocellular carcinoma, and chronic hepatitis C is a major indication for liver transplantation. Effective treatment is required to prevent these outcomes.
Current treatment consists of a combination of peginterferon (PegIFN) and ribavirin (RBV) given for 24 or 48 weeks depending on the viral genotype. While genotypes 2 and 3 respond well to 24 weeks of PegIFN/RBV with approximately 80% viral clearance, genotype 1 infected patients only achieve about 40-50% sustained viral response (SVR) with 48 weeks of combination therapy.
RBV is a nucleoside analog with structural similarities to guanosine, which modulates RNA and DNA synthesis. RBV reveals antiviral activity against respiratory syncytial (RS)-virus, influenza virus, Lassa virus uand others. The exact mode of antiviral activity is yet unknown but believed to relate to reducing survival of HCV-infected hepatocytes thereby allowing for elimination of infected cells by interferon-stimulated immune mechanisms.
Generally, RBV is well tolerated. With standard daily doses between 1.000 and 1.200mg, irritability, sleeping abnormalities, cough and pruritus. The most prevalent and typical side effect of RBV is a dose-dependent hemolytical anemia which responds well to dose reduction or interruption of RBV therapy. RBV-associated anemia impairs quality of life and, overall, 25-36% of patients require dose reductions and/or RBV cessation. However, reduction/cessation of RBV is associated with a significant drop of SVR and measures to maintain RBV doses are clearly warranted. Several recent studies have shown that erythropoetin can counteract RBV-induced hemolytic anemia, and improve quality of life.
The relevance of RBV dose with regard to therapeutic response to combination therapy is well-established and currently, RBV is dosed according to weight: patients with CHC genotype 1 are treated with 1.000mg if body weight is <65kg, and receive 1.200mg if >65kg.
Retrospective studies have shown that relapsers and non-responders to antiviral treatment with RBV had lower RBV levels than those who had a SVR. In a retrospective analysis of 4 studies investigating a total of 1105 patients treated with RBV, RBV plasma concentrations measured at 4 weeks of treatment correlated with viral clearance: SVR was 31.8% in those with RBV levels <1,000ng/ml, and increased to 62.5% with RBV concentrations at >4,000ng/ml.
A pilot trial from Sweden investigated whether dosing RBV according to a plasma level of 15mcmol/l (3.7mcg/ml) in 10 patients. Median RBV dose was 2.540mg/day and all patients received erythropoetin.SVR was achieved in 9 of 10 patients.
So far, a randomized, controlled trial comparing weight-based RBV (standard) vs. RBV dosed according to kidney function and plasma levels.
Objective
Comparison of efficacy and tolerability of treatment with PegIFN-alpha 2a + RBV dosed according plasma concentrations vs PegIFN-alpha 2a + weight-based RBV in patients with chronic hepatitis C genotype 1
Methods
Prospective, controlled, open label randomized human trial
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Basel, Schweiz, CH-4031
- Dept of Gastroenterology, University of Basel
-
Bern, Schweiz, CH-3010
- Institute of Clinical Pharmacology and Visceral Research, University of Bern
-
Lausanne, Schweiz, CH-1011
- Division of Gastroenterology, University of Lausanne
-
St. Gallen, Schweiz, CH-9007
- Kantonsspital St.Gallen
-
Zürich, Schweiz, Ch-8037
- Stadtspital Waid, Zürich
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Male and female patients aged 18-65 years
- Elevated liver enzymes levels
- Compensated liver disease
- Available liver histology confirming METAVIR F2 fibrosis
- Written consent to participation
Exclusion Criteria
- Age <18, >65
- Prior ribavirin treatment
- Intolerance towards ribavirin, PegIFN or erythropoetin
- Pregnancy or breast feeding
- Relevant cardiovascular or pulmonary disease
- Kidney insufficiency (creatinine clearance <50ml/min)
- Coinfection with HIV or hepatitis B virus
- Hepatic comorbidities (hemochromatosis, Wilson's disease, autoimmune disorders)
- Alcohol consumption > 40g/day
- Psychiatric disorders
- Malignancy (except for basalioma)
- Active consumption of illicit drugs
- Participation in another trial shorter than 3 months prior to inclusion
- Lack of consent
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: A
PegIFN-alpha 2a + RBV (commenced according to kidney function) adjusted to plasma levels.
Treatment with erythropoetin 3x3,000IU/week up to 3x10,000IU/week in case of hemolytic anemia
|
Ribavirin dose started according to kidney function (usually 1,800mg) and adapted according to plasma level during follow-up
|
Aktiv komparator: B
PegIFN-alpha 2a + RBV (weight based; 1,000 or 1,200 mg/day)
|
Ribavirin dose started at 1,000mg (body weight <65kg) or 1,200mg (body weight equal or >65kg)
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Sustained virological response
Tidsram: 1 Day
|
1 Day
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Adverse Events
Tidsram: day 1 until 24 weeks after end or treatment
|
day 1 until 24 weeks after end or treatment
|
Rapid virological response at 4 weeks of treatment
Tidsram: 4 weeks
|
4 weeks
|
Early virological response at 12 weeks of treatment
Tidsram: 12 weeks
|
12 weeks
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Felix Stickel, MD, Institute for Clinical Pharmacology and Visceral Research, University of Bern
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- RNA-virusinfektioner
- Virussjukdomar
- Infektioner
- Blodburna infektioner
- Smittsamma sjukdomar
- Leversjukdomar
- Flaviviridae-infektioner
- Hepatit, Viral, Human
- Enterovirusinfektioner
- Picornaviridae-infektioner
- Hepatit
- Hepatit A
- Hepatit C
- Hepatit, kronisk
- Hepatit C, kronisk
- Molekylära mekanismer för farmakologisk verkan
- Anti-infektionsmedel
- Antivirala medel
- Antimetaboliter
- Ribavirin
Andra studie-ID-nummer
- 091/07
- ML21071
- SASL-24
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Kronisk hepatit C
-
Clínica de Oftalmología de Cali S.AAvslutadMeibomisk körteldysfunktion | Eyes Dry ChronicColombia
-
Alcon ResearchAvslutad
-
Jules Bordet InstituteMacopharma; Belgian Hematological SocietyRekryteringRefractory Chronic Graft Versus Host Disease (cGVHD)Belgien
-
Dhulikhel HospitalKathmandu University School of Medical SciencesIndragenPostoperativ analgesi | CSOM - Chronic Suppurative Otitis MediaNepal
-
Dokuz Eylul UniversityEge UniversityAvslutadMMP9 | TIMP1 | MMP9 -1562 C/T | TIMP1 372 T/CKalkon
-
Tripep ABInovio PharmaceuticalsOkändKronisk hepatit C-virusinfektionSverige
-
Johann Wolfgang Goethe University HospitalAvslutad
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsIndragenKronisk hepatit C-virusinfektionIsrael
-
Hadassah Medical OrganizationOkändKronisk hepatit C-virusinfektionIsrael
-
Trek Therapeutics, PBCAvslutadKronisk hepatit C | Hepatit C genotyp 1 | Hepatit C (HCV) | Hepatit C virusinfektionFörenta staterna, Nya Zeeland
Kliniska prövningar på High ribavirin dose
-
University of MinnesotaRekryteringFast organtransplantationFörenta staterna
-
Sanofi Pasteur, a Sanofi CompanyAvslutadFriska volontärer | InfluensavaccinationFörenta staterna
-
University of RochesterHar inte rekryterat ännuPediatrisk astma
-
The University of Texas at DallasUniversity of Texas Southwestern Medical CenterRekryteringMinnesstörningar | Svårighet att hitta ordFörenta staterna
-
National Taiwan University HospitalOkänd
-
Boehringer IngelheimAvslutadHepatit C, kroniskFörenta staterna, Tyskland, Spanien, Storbritannien
-
Merck Sharp & Dohme LLCAvslutad
-
University of California, San DiegoPatient-Centered Outcomes Research Institute; University of Massachusetts... och andra samarbetspartnersAvslutadPatientengagemang | Läkar-patient relationer | Läkarens roll | PatientaktiveringFörenta staterna
-
Centre Hospitalier Universitaire de BesanconCentre Hospitalier Universitaire Dijon; Poitiers University Hospital; University... och andra samarbetspartnersRekrytering
-
David BüchserRekrytering